Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Gene

PTEN

6 articles · Resources: NCBI Gene, OncoKB

Clinical · Molecular biology · Bioinfo & AI

Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer: a prospective observational study

Amghar M, Hielscher T, Rausch T, et al.

BMC cancer

This prospective observational study investigated the prognostic value of circulating tumor DNA (ctDNA)-derived tumor fraction (TFx) and copy-number alterations (CNAs) in 78 patients with metastatic castration-resistant prostate cancer (mCRPC) receiving tandem [225Ac]Ac-/[177Lu]Lu-PSMA-617 radioligand therapy. Findings revealed that ctDNA-derived TFx serves as a dynamic biomarker for treatment response and progression risk, with a significantly increased risk of progression (HR 4.9) when modeled as a time-dependent variable. Furthermore, a high CNA burden was associated with shorter median overall survival (8.3 vs 13.8 months). The study identified recurrent CNAs affecting key tumor suppressor genes and highlighted the potential of these ctDNA-based biomarkers for clinical stratification and real-time monitoring.

Clinical · Molecular biology · Bioinfo & AI

Genomic Characteristics of Leiomyosarcoma: An AACR Project GENIE Study

Ali H, Chander C, Torbenson E, et al.

Anticancer research

This study characterized the genomic landscape of leiomyosarcoma, a rare and aggressive tumor, by analyzing a large dataset from the AACR Project GENIE. Researchers examined over 1,000 tumor samples, identifying the most frequent somatic mutations and copy number alterations. TP53, RB1, and ATRX were the most commonly altered genes, with homozygous deletions of RB1 and TP53, and MAP2K4 amplifications. The study also highlighted enriched IGF2 and AXIN1 alterations in metastatic samples, suggesting their potential role in disease progression. These findings enhance the understanding of leiomyosarcoma biology and could guide future precision oncology strategies.

Clinical · Molecular biology

Multi-omics profiling unveils biological and clinical insights into pulmonary sarcomatoid carcinoma

Sun L, Wang J, Yan Y, et al.

Cell reports. Medicine

This study conducted a comprehensive multi-omics analysis of pulmonary sarcomatoid carcinoma (PSC), a rare and aggressive lung cancer. Integrating whole-exome sequencing, transcriptomic, proteomic, and phosphoproteomic data from 86 patients, alongside single-cell RNA sequencing, researchers characterized this poorly understood disease. They identified an elevated ferroptosis suppression signature, making tumors vulnerable to targeting FTL and SLC3A2. The study also revealed distinct patient subtypes based on proteomic profiling and highlighted the role of epithelial-mesenchymal transition in tumor progression and immunotherapy resistance.

Clinical · Molecular biology

Gene Expression Profiling of EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, and TP53 in Cell-Free RNA From Exhaled Breath Condensate: Diagnostic, Prognostic, and Therapeutic Implications in Advanced Lung Adenocarcinoma

Latifova S, Genis U, Karakus HS, et al.

Cancer reports (Hoboken, N.J.)

This prospective study evaluated gene expression profiling of seven genes (EGFR, FGFR2, PIK3CA, PTEN, SMAD4, STK11, TP53) in cell-free RNA (cfRNA) from exhaled breath condensate (EBC) in patients with advanced lung adenocarcinoma. Results indicated that PIK3CA showed the best diagnostic performance in distinguishing patients from healthy controls. High expression of FGFR2 and PIK3CA was associated with significantly shorter overall survival, highlighting their prognostic relevance. EGFR expression demonstrated a strong correlation between EBC and plasma, and low EGFR expression was linked to longer survival in patients receiving chemotherapy alone. This non-invasive EBC-based approach offers potential for molecular characterization and patient stratification.

Clinical · Molecular biology · Bioinfo & AI

Assessing biomarkers for patients with breast cancer who are suited for adjuvant therapy

Rakha EA

Expert review of molecular diagnostics

This review examines established and emerging biomarkers for stratifying patients with early-stage breast cancer to optimize adjuvant systemic therapy. It highlights that while clinicopathological factors remain fundamental, decision-making is increasingly driven by precise biological markers. ER and HER2 status are crucial, and multigene assays refine recurrence risk and chemotherapy benefit in hormone receptor-positive cancers. Immune and DNA-repair biomarkers inform targeted therapies in HER2-positive and triple-negative subtypes, while mutation profiling of genes like ESR1, PIK3CA, AKT, MTOR, and PTEN guides targeted treatments. Emerging approaches, including liquid biopsy and artificial intelligence, offer dynamic insights but require prospective validation.

Clinical · Molecular biology

The impact of next generation sequencing studies on the diagnosis of BAP1 inactivated melanocytic tumors

Braat J, Trichy NS, Holic LJ, et al.

Human pathology

This study investigates the impact of next-generation sequencing (NGS) on the diagnosis of BAP1 inactivated melanocytic tumors (BIMTs), which often exhibit significant morphological atypia, complicating their classification. A survey among dermatopathologists revealed that incorporating NGS results significantly improved diagnostic accuracy and interobserver agreement. Specific genomic aberrations, including pathogenic variants in TERT-p, CDKN2A, PTEN, and MYC amplification, were found exclusively in malignant cases. These findings suggest that NGS could refine melanoma diagnosis, which is critical for guiding access to effective therapies.